RU2001125674A - Nicotine-based transdermal therapeutic system additionally containing monoterpenetones - Google Patents

Nicotine-based transdermal therapeutic system additionally containing monoterpenetones

Info

Publication number
RU2001125674A
RU2001125674A RU2001125674/14A RU2001125674A RU2001125674A RU 2001125674 A RU2001125674 A RU 2001125674A RU 2001125674/14 A RU2001125674/14 A RU 2001125674/14A RU 2001125674 A RU2001125674 A RU 2001125674A RU 2001125674 A RU2001125674 A RU 2001125674A
Authority
RU
Russia
Prior art keywords
nicotine
therapeutic system
monoterpenketone
transdermal therapeutic
essential oil
Prior art date
Application number
RU2001125674/14A
Other languages
Russian (ru)
Other versions
RU2228740C2 (en
Inventor
Стефан БРАХТ
Original Assignee
Лтс Ломанн Терапи-Зюстеме Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19913732A external-priority patent/DE19913732A1/en
Application filed by Лтс Ломанн Терапи-Зюстеме Аг filed Critical Лтс Ломанн Терапи-Зюстеме Аг
Publication of RU2001125674A publication Critical patent/RU2001125674A/en
Application granted granted Critical
Publication of RU2228740C2 publication Critical patent/RU2228740C2/en

Links

Claims (13)

1. Чрескожная терапевтическая система, состоящая из подложки, по меньшей мере, одного содержащего никотин слоя или участка, способного обладать способностью приклеиваться при надавливании, а также удаляемого защитного слоя, отличающаяся тем, что она содержит, по меньшей, мере одно эфирное масло, извлеченное из одной из разновидностей мяты, либо, по меньшей мере, один монотерпенкетон, содержащийся в таких эфирных маслах.1. Transdermal therapeutic system, consisting of a substrate of at least one nicotine-containing layer or area capable of being glued under pressure, as well as a removable protective layer, characterized in that it contains at least one essential oil extracted from one of the varieties of mint, or at least one monoterpenketone contained in such essential oils. 2. Чрескожная терапевтическая система по п.1, отличающаяся тем, что монотерпенкетон представляет собой одно из соединений группы, включающей карвон, дигидрокарвон, ментон, изопулегон, изоментон, неоментон, неоизоментон или пиперитон.2. The transdermal therapeutic system according to claim 1, characterized in that monoterpenketone is one of the compounds of the group comprising carvone, dihydrocarvone, menton, isopulegon, isomenton, neomenton, neoisomenton or piperitone. 3. Чрескожная терапевтическая система по п.2, отличающаяся тем, что монотерпенкетоны используют в качестве зеркальных изомеров в чистом виде либо в виде их смесей.3. The transdermal therapeutic system according to claim 2, characterized in that monoterpenetones are used as mirror isomers in pure form or as mixtures thereof. 4. Чрескожная терапевтическая система по п.1, отличающаяся тем, что в качестве эфирного масла используют масло мяты курчавой (Oleum Mentae crispae).4. The transdermal therapeutic system according to claim 1, characterized in that curly peppermint oil (Oleum Mentae crispae) is used as the essential oil. 5. Чрескожная терапевтическая система по одному или нескольким предшествующим пунктам, отличающаяся тем, что содержание монотерпенкетона(-ов) в содержащей никотин основе составляет от 0,1 до 5,0 мас.%, предпочтительно, - от 0,5 до 2 мас.%.5. Percutaneous therapeutic system according to one or more of the preceding paragraphs, characterized in that the content of monoterpenketone (s) in the nicotine-containing base is from 0.1 to 5.0 wt.%, Preferably from 0.5 to 2 wt. % 6. Способ маскировки неприятного запаха чрескожной терапевтической системы, вызванного содержащимся в ней никотином, отличающийся тем, что в чрескожную терапевтическую систему на основе никотина добавляют, по меньшей мере, одно улучшающее запах вещество, представляющее собой эфирное масло, извлеченное из одной из разновидностей мяты, либо монотерпенкетон, содержащийся в эфирном масле, извлеченном из одной из разновидностей мяты.6. A method for masking the unpleasant odor of a transdermal therapeutic system caused by the nicotine contained therein, characterized in that at least one odor improving substance, which is an essential oil extracted from one of the varieties of mint, is added to the transdermal therapeutic system based on nicotine, or monoterpenketone contained in essential oil extracted from one of the varieties of mint. 7. Способ по п.6, отличающийся тем, что эфирное масло представляет собой масло мяты курчавой (Oleum Mentae crispae).7. The method according to claim 6, characterized in that the essential oil is curly peppermint oil (Oleum Mentae crispae). 8. Способ по п.6, отличающийся тем, что монотерпенкетон представляет собой одно из соединений группы, включающей карвон, дигидрокарвон, ментон, изопулегон, изоментон, неоментон, неоизоментон или пиперитон.8. The method according to claim 6, characterized in that monoterpenketone is one of the compounds of the group comprising carvone, dihydrocarvone, menton, isopulegone, isomenton, neomenton, neoisomenton or piperitone. 9. Способ по п.8, отличающийся тем, что монотерпенкетона(-ы) добавляют в содержащую никотин основу в количества, предпочтительно, от 0,1 до 5,0 мас.%, особо предпочтительно, в количестве от 0,5 до 2 мас.%.9. The method according to claim 8, characterized in that monoterpenketone (s) are added to the nicotine-containing base in an amount of preferably from 0.1 to 5.0 wt.%, Particularly preferably in an amount of from 0.5 to 2 wt.%. 10. Использование эфирного масла, извлеченного из одной из разновидностей мяты, и/или монотерпенкетона, содержащегося в эфирном масле, извлеченном из одной из разновидностей мяты, для маскировки неприятного запаха чрескожной терапевтической системы, вызванного никотином, содержащимся в упомянутой чрескожной терапевтической системе никотином.10. The use of an essential oil extracted from one of the mint varieties and / or monoterpenketone contained in an essential oil extracted from one of the mint varieties to mask the unpleasant odor of the transdermal therapeutic system caused by nicotine contained in said transdermal therapeutic system by nicotine. 11. Использование по п.10, отличающееся тем, что монотерпенкетон, представляет собой одно из соединений группы, включающей карвон, дигидрокарвон, ментон, изопулегон, изоментон, неоментон, неоизоментон или пиперитон.11. The use according to claim 10, characterized in that monoterpenketone is one of the compounds of the group comprising carvone, dihydrocarvone, menton, isopulegone, isomenton, neomenton, neoisomenton or piperitone. 12. Использование по п.11, отличающееся тем, что монотерпенкетон(-ы) добавляют в содержащую никотин основу предпочтительно в количестве от 0,1 до 5,0 мас.%, особо предпочтительно, в количестве от 0,5 до 2 мас.%.12. The use according to claim 11, characterized in that the monoterpenketone (s) are added to the nicotine-containing base, preferably in an amount of from 0.1 to 5.0 wt.%, Particularly preferably in an amount of from 0.5 to 2 wt. % 13. Использование по п.10, отличающееся тем, что эфирное масло представляет собой масло мяты курчавой (Oleum Mentae crispae).13. The use of claim 10, wherein the essential oil is curly peppermint oil (Oleum Mentae crispae).
RU2001125674/15A 1999-03-26 2000-03-21 Nicotine-base percutaneous therapeutic system comprising monoterpene ketones additionally RU2228740C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19913732.3 1999-03-26
DE19913732A DE19913732A1 (en) 1999-03-26 1999-03-26 Nicotine TTS with the addition of monoterpene ketones

Publications (2)

Publication Number Publication Date
RU2001125674A true RU2001125674A (en) 2003-07-27
RU2228740C2 RU2228740C2 (en) 2004-05-20

Family

ID=7902491

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001125674/15A RU2228740C2 (en) 1999-03-26 2000-03-21 Nicotine-base percutaneous therapeutic system comprising monoterpene ketones additionally

Country Status (23)

Country Link
US (1) US7029692B1 (en)
EP (1) EP1164996B1 (en)
JP (1) JP4750282B2 (en)
KR (1) KR100597802B1 (en)
CN (1) CN1199623C (en)
AR (1) AR027485A1 (en)
AT (1) ATE252356T1 (en)
AU (1) AU769656B2 (en)
BR (1) BR0010515A (en)
CA (1) CA2367615C (en)
CZ (1) CZ300409B6 (en)
DE (2) DE19913732A1 (en)
DK (1) DK1164996T3 (en)
ES (1) ES2211523T3 (en)
HU (1) HUP0200189A3 (en)
IL (1) IL145502A0 (en)
NZ (1) NZ514423A (en)
PT (1) PT1164996E (en)
RU (1) RU2228740C2 (en)
TR (1) TR200102605T2 (en)
TW (1) TWI227666B (en)
WO (1) WO2000057824A1 (en)
ZA (1) ZA200107864B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
PT1670433E (en) 2003-10-10 2012-02-08 Ferring Bv Transdermal pharmaceutical formulation for minimizing skin residues
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (en) 2005-07-11 2007-03-23 삼성전기주식회사 Output buffer circuit
DE102005033543A1 (en) * 2005-07-14 2007-01-18 Grünenthal GmbH A fragrance-containing transdermal therapeutic system
IL177071A0 (en) * 2005-08-01 2006-12-10 Nitto Denko Corp Method of preparing a nicotine transdermal preparation
ES2499067T3 (en) * 2005-10-13 2014-09-26 Nitto Denko Corporation Transdermal preparation of nicotine and its production method
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
CN101264277B (en) * 2008-04-16 2012-09-26 冯冲 Compound essential oil for controlling smoke and giving up smoking
JP2013523092A (en) * 2010-03-26 2013-06-17 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム Suppression of sensory stimulation during consumption of non-smoking tobacco products
JP5730355B2 (en) * 2013-07-24 2015-06-10 学校法人近畿大学 CYP2A13 inhibitor
JP6888974B2 (en) * 2016-01-27 2021-06-18 学校法人近畿大学 Compounds with CYP2A13 inhibitory activity and CYP2A13 inhibitors
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3559655A (en) * 1969-02-25 1971-02-02 Sutton Res Corp Oxidized cellulose substitute smoking material and method of making same
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
JPH01157921A (en) * 1987-12-15 1989-06-21 Tsumura & Co Production of pharmaceutical for double blind test
JPH01290608A (en) * 1988-05-18 1989-11-22 Sunstar Inc Germicidal composition
EP0356382B1 (en) * 1988-08-02 1994-02-16 Ciba-Geigy Ag Multilayer plaster
JP2905210B2 (en) * 1989-01-23 1999-06-14 フロイント産業株式会社 Transdermal and transmucosal absorption enhancers and transdermal and transmucosal preparations
JPH0748190B2 (en) * 1990-01-22 1995-05-24 株式会社東芝 Microprocessor with cache memory
JPH0679002A (en) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc Patch device for percutaneous administration
JPH06181972A (en) * 1992-12-18 1994-07-05 Kanebo Ltd Deodorant for cigarette smell
US5520924A (en) * 1993-07-09 1996-05-28 Mizu Systems Corporation Methods and articles for administering drug to the oral cavity
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE4332094C2 (en) * 1993-09-22 1995-09-07 Lohmann Therapie Syst Lts Active substance plaster which can be produced without solvent and process for its preparation
JPH07133490A (en) * 1993-11-10 1995-05-23 Pola Chem Ind Inc Deodorant
AU2703795A (en) * 1994-06-23 1996-01-19 Procter & Gamble Company, The Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
JPH09110680A (en) * 1995-10-19 1997-04-28 Yuutoku Yakuhin Kogyo Kk Dermatitis-curing strap
JPH10130118A (en) * 1996-10-25 1998-05-19 Lion Corp Composition of preparation for external use
JPH10306030A (en) * 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd External preparation composition

Similar Documents

Publication Publication Date Title
RU2001125674A (en) Nicotine-based transdermal therapeutic system additionally containing monoterpenetones
RU2228740C2 (en) Nicotine-base percutaneous therapeutic system comprising monoterpene ketones additionally
ATE525061T1 (en) SOLID SELF-ADHESIVE COMPOSITIONS FOR THE TOPICAL TREATMENT OF DISORDERS OF THE ORAL MUCOSA
ATE556697T1 (en) COSMETIC COMPOSITION CONTAINING A VOLATILE FAT PHASE
BR9810729B1 (en) pharmaceutical composition for acid lipophilic compounds arranged as a self-emulsifying formulation.
ES2269149T3 (en) COLLECTION METHOD OF FRAGRANCE INGREDIENT, COMPOSITION FOR PERFURME AND COSMETIC PRODUCTS CONTAINING IT.
RU2000116545A (en) Antiperspirant or deodorant compositions
CN1784210A (en) Sprayable perfume with an improved tenacity
RU2000116547A (en) USE OF SUBSTITUTED AMINOMETHYL-CHROMANS FOR PREVENTION OF DEGENERATION AND FOR ACCELERATION OF NERVE CELL REGENERATION
AR008506A1 (en) PHARMACEUTICAL COMPOSITION.
DE69824296D1 (en) COMPOSITIONS FOR TREATING LUNG DISEASES WITH OPTICALLY PURE S-SALMETEROL
FR2800607B1 (en) COMPOSITION CONTAINING A HYDROPHILIC ACTIVE ACTIVE AND ITS USE IN COSMETICS
DE69501183D1 (en) Solid oral pharmaceutical preparation with gemfibrozil as an active ingredient and manufacturing method
JPH108321A (en) Heat-protecting helmet including aromatic substance
JPH07194683A (en) Deodorant
DE50208267D1 (en) COMPOSITION OF ACTIVE SUBSTANCES FOR THE MEDICINAL THERAPY OF NICOTINE DEPENDENCE
RU99106789A (en) ANHYDROUS POTENTIAL COMPOSITION
JP2003321696A (en) Method for extracting rose flower ingredient
JPS60261458A (en) Production of deodorant
JPS60174153A (en) Deodorant
KR20050019595A (en) Perfume composition
JPH05309126A (en) Odor removing method and deodorant
JPH07163645A (en) Deodorant
FR2565824A1 (en) Composition for dispersion in the atmosphere, counteracting the craving to smoke tobacco
KR930021220A (en) Deodorant Using Grape Skin Extract